Differential metabolites facilitate metabolic dysfunction-associated fatty liver disease malignancy via immune evasion and M2-polarized macrophages

Figure 5 Gene transcripts of immune cells during metabolic dysfunction-associated fatty liver disease malignancy progression. A: Gene transcripts of hepatic immune cells; B: Transcript numbers of genes whose expression was upregulated or downregulated from healthy liver to metabolic dysfunction-associated fatty liver disease; C: Transcript numbers of genes whose expression increased or decreased from metabolic dysfunction-associated fatty liver disease to hepatocellular carcinoma; D: Interaction analysis of hepatic immune cells; E: Macrophages with immune cells in the programmed death ligand 1-activating network. MAFLD: Metabolic dysfunction-associated fatty liver disease; MASH: Metabolic dysfunction-associated steatohepatitis; HCC: Hepatocellular carcinoma.